Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fumaric acid esters and narrow band UVB in severe plaque psoriasis
NCT01321164Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- Apr 2011
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dimethyl fumarate + ethyl hydrogen fumarate in plaque psoriasis, sponsored by Medical University of Vienna. Primary endpoint: Mean reduction in Psoriasis Area and Severity Index at 6 weeks. Started Apr 2011; status: completed.
02
Drugs
dimethyl fumarate + ethyl hydrogen fumarate
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01321164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01321164.